Trials / Terminated
TerminatedNCT02014116
A Study of LY3009120 in Participants With Advanced Cancer or Cancer That Has Spread to Other Parts of Their Body
A Phase 1 Study of LY3009120 in Patients With Advanced or Metastatic Cancer
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 51 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of this study is to see how safe the investigational drug known as LY3009120 is and whether it will work to help people with advanced cancer or cancer that has spread to other parts of the body.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LY3009120 capsule | Administered orally. |
Timeline
- Start date
- 2013-11-26
- Primary completion
- 2017-04-07
- Completion
- 2018-10-05
- First posted
- 2013-12-18
- Last updated
- 2019-12-27
- Results posted
- 2019-12-27
Locations
6 sites across 4 countries: United States, Australia, France, Spain
Source: ClinicalTrials.gov record NCT02014116. Inclusion in this directory is not an endorsement.